Author's Comment Thomas Barnard Comments174 | + F
Post# of 36536
Comments174 | + Follow
Author’s reply »
Leronlimab may be useful for extreme cases with the cytokine storms, but many of us older folks are hoping that companies like Generex (GNBT) will stay the course because the epidemiologists say this disease is now out in the general population from here forward. Generex's Ii-key technology may be one of the best for vaccine development, which could save us from catching one of these horrible cases.